Table 1 Baseline characteristics in the overall population
Overall Population | ||||||
|---|---|---|---|---|---|---|
PS-Matched | PS-Trimmed | |||||
At time of initiation | Abatacept N = 111 | TNF N = 111 | Standardized Difference | Abatacept N = 170 | TNF N = 157 | Standardized Difference |
Age (years), Mean (SD) | 56.2 (12.5) | 57.6 (12.3) | 0.11 | 56.6 (12.9) | 56.9 (12.4) | 0.03 |
Female, n (%) | 82 (73.9) | 81 (73.0) | 0.02 | 126 (74.1) | 108 (68.8) | 0.12 |
White, n (%) | 107 (98.2) | 99 (90.0) | 0.35 | 166 (98.8) | 143 (92.9) | 0.30 |
Medicaid, n (%) | 9 (8.1) | 7 (6.3) | 0.07 | 15 (8.8) | 10 (6.4) | 0.09 |
Full/Part time work, n (%) | 54 (48.7) | 55 (49.6) | 0.02 | 85 (50.0) | 75 (47.8) | 0.04 |
Retired, n (%) | 23 (20.7) | 27 (24.3) | 0.09 | 32 (18.8) | 41 (26.1) | 0.17 |
Disabled, n (%) | 18 (16.2) | 21 (18.9) | 0.07 | 34 (20.0) | 27 (17.2) | 0.07 |
Never smoker, n (%) | 42 (37.8) | 43 (38.7) | 0.02 | 69 (40.6) | 63 (40.1) | 0.01 |
Former smoker, n (%) | 41 (36.9) | 38 (34.2) | 0.06 | 58 (34.1) | 58 (36.9) | 0.06 |
Current smoker, n (%) | 28 (25.2) | 30 (27.0) | 0.04 | 43 (25.3) | 36 (22.9) | 0.06 |
BMI, Obese (≥ 30), n (%) | 42 (37.8) | 34 (30.6) | 0.15 | 67 (39.4) | 55 (35.0) | 0.09 |
Hypertension, n (%) | 37 (33.3) | 38 (34.2) | 0.02 | 60 (35.3) | 50 (31.9) | 0.07 |
Prior serious Infections, n (%) | 6 (5.4) | 6 (5.4) | 0.00 | 11 (6.5) | 8 (5.1) | 0.06 |
Cardiovascular, n (%) | 18 (16.2) | 18 (16.2) | 0.00 | 26 (15.3) | 24 (15.3) | 0.00 |
Duration of RA year, Mean (SD) | 10.5 (10.6) | 11.4 (10.8) | 0.09 | 11.4 (10.2) | 10.4 (10.8) | 0.10 |
CDAI, Mean (SD) | 27.5 (12.4) | 27.2 (11.6) | 0.03 | 27.8 (11.8) | 27.5 (11.9) | 0.02 |
TJC, Mean (SD) | 9.6 (6.4) | 9.4 (6.9) | 0.03 | 9.9 (6.3) | 9.8 (7.0) | 0.01 |
SJC, Mean (SD) | 7.6 (5.4) | 7.4 (4.5) | 0.03 | 7.7 (5.4) | 7.7 (4.9) | 0.00 |
CRP, Mean (SD) | 10.5 (15.2) | 10.4 (14.6) | 0.01 | 10.0 (14.6) | 10.7 (15.1) | 0.05 |
DAS28-CRP, Mean (SD) | 4.7 (1.1) | 4.7 (1.0) | 0.03 | 4.7 (1.1) | 4.7 (1.0) | 0.05 |
RF, Mean (SD) | 203.7 (283.0) | 177.4 (260.8) | 0.10 | 192.3 (262.9) | 180.5 (247.5) | 0.05 |
RF+, n (%) | 99 (89.2) | 99 (89.2) | 0.00 | 155 (91.2) | 138 (87.9) | 0.11 |
mHAQ, Mean (SD) | 0.5 (0.5) | 0.5 (0.5) | 0.01 | 0.5 (0.5) | 0.5 (0.5) | 0.05 |
PGA (VAS 0-100), Mean (SD) | 49.8 (21.0) | 51.3 (17.4) | 0.08 | 48.3 (19.5) | 50.8 (18.9) | 0.13 |
PtGA (VAS 0-100), Mean (SD) | 53.0 (23.4) | 52.0 (23.8) | 0.05 | 54.0 (23.5) | 49.9 (24.8) | 0.17 |
Pain (VAS 0-100), Mean (SD) | 53.1 (23.9) | 53.0 (27.2) | 0.00 | 54.8 (24.4) | 51.2 (28.3) | 0.14 |
Fatigue (VAS 0-100), Mean (SD) | 55.5 (28.3) | 54.1 (29.5) | 0.05 | 56.1 (27.7) | 51.9 (29.4) | 0.15 |
Biologic Naïve, n Yes, n (%) | 111 19 (17.1) | 111 19 (17.1) | 0.00 | 170 25 (14.7) | 157 28 (17.8) | 0.08 |
Prior csDMARD usage count, Mean (SD) | 1.1 (1.1) | 1.2 (1.2) | 0.09 | 1.3 (1.3) | 1.1 (1.2) | 0.17 |
Prior TNFi usage count, n | 111 | 111 | 170 | 157 | ||
0, n (%) | 20 (18.0) | 21 (18.9) | 0.02 | 26 (15.3) | 31 (19.8) | 0.12 |
1, n (%) | 53 (47.8) | 50 (45.1) | 0.05 | 60 (35.3) | 84 (53.5) | 0.37 |
2+, n (%) | 38 (34.2) | 40 (36.0) | 0.04 | 84 (49.4) | 42 (26.8) | 0.48 |
Prior non-TNFi usage count, n | 111 | 111 | 170 | 157 | ||
0, n (%) | 99 (89.2) | 105 (94.6) | 0.20 | 148 (87.1) | 148 (94.3) | 0.25 |
1, n (%) | 10 (9.0) | 6 (5.4) | 0.14 | 18 (10.6) | 9 (5.7) | 0.18 |
2+, n (%) | 2 (1.8) | 0 (0.0) | 0.19 | 4 (2.4) | 0 (0.0) | 0.22 |
Prior biologic usage count, n | 111 | 111 | 170 | 157 | ||
0, n (%) | 19 (17.1) | 19 (17.1) | 0.00 | 25 (14.7) | 28 (17.8) | 0.08 |
1, n (%) | 49 (44.1) | 49 (44.1) | 0.00 | 54 (31.8) | 83 (52.9) | 0.44 |
2, n (%) | 28 (25.2) | 37 (33.3) | 0.18 | 57 (33.5) | 38 (24.2) | 0.21 |
3+, n (%) | 15 (13.5) | 6 (5.4) | 0.28 | 34 (20.0) | 8 (5.1) | 0.46 |
Current Prednisone use, n | 111 | 111 | 170 | 157 | ||
Yes, n (%) | 52 (46.9) | 44 (39.6) | 0.15 | 74 (43.5) | 67 (42.7) | 0.02 |
Prednisone dose, n | 52 | 43 | 73 | 66 | ||
Mean (SD) | 7.6 (4.6) | 7.3 (4.2) | 0.07 | 7.4 (5.0) | 7.4 (3.9) | 0.01 |
MTX dose, n | 54 | 56 | 87 | 83 | ||
Mean (SD) | 17.4 (5.3) | 17.4 (4.7) | 0.00 | 17.8 (5.2) | 17.7 (4.9) | 0.02 |
Mono and Combo Therapy | ||||||
Monotherapy | 39 (35.1) | 38 (34.2) | 0.06 | 56 (32.9) | 51 (32.5) | 0.07 |
Combo with MTX | 44 (39.6) | 47 (42.3) | 73 (42.9) | 72 (45.9) | ||
Combo with non-MTX csDMARD | 17 (15.3) | 16 (14.4) | 26 (15.3) | 22 (14.0) | ||
Combo with MTX & non-MTX csDMARD | 11 (9.9) | 10 (9.0) | 15 (8.8) | 12 (7.6) | ||